Compare WALD & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WALD | PROF |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 199.3M |
| IPO Year | 2021 | N/A |
| Metric | WALD | PROF |
|---|---|---|
| Price | $1.89 | $7.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $4.76 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 183.3K | 99.1K |
| Earning Date | 11-24-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $274,560,000.00 | $14,297,000.00 |
| Revenue This Year | $4.61 | $64.23 |
| Revenue Next Year | $11.22 | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.22 | ★ 67.94 |
| 52 Week Low | $1.48 | $3.76 |
| 52 Week High | $4.18 | $7.99 |
| Indicator | WALD | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 70.78 |
| Support Level | $2.18 | $7.10 |
| Resistance Level | $2.25 | $7.53 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 10.88 | 95.76 |
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.